{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T23:03:15Z","timestamp":1784674995074,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":64,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Romanian National Society of Medical Oncology","award":["The Article Processing Charges were funded by the Romanian National Society of Medical Oncology (SNOMR)."],"award-info":[{"award-number":["The Article Processing Charges were funded by the Romanian National Society of Medical Oncology (SNOMR)."]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-52006-8","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T21:44:12Z","timestamp":1779227052000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The therapeutic potential of antibody-drug conjugates in advanced colorectal cancer: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"16","author":[{"given":"Daniel","family":"Sur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ionut-Constantin","family":"Coroama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alecsandra","family":"Gorzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian Virgil","family":"Lungulescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adina","family":"Turcu-Stiolica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"52006_CR1","unstructured":"International Agency for Research on Cancer (IARC). Cancer Today: Europe, colorectal cancer (ICD-O 41), new cases and deaths. (2020). https:\/\/gco.iarc.fr\/today\/en\/dataviz\/tables?mode=population&cancers=41&group_populations=0&multiple_populations=1&types=1 (2020)."},{"key":"52006_CR2","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","volume":"27","author":"E Van Cutsem","year":"2016","unstructured":"Van Cutsem, E., Cervantes, A. & Adam, R. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann. Oncol. 27, 1386\u20131422 (2016).","journal-title":"Ann. Oncol."},{"key":"52006_CR3","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ctrv.2017.04.007","volume":"59","author":"A Vogel","year":"2017","unstructured":"Vogel, A., Hofheinz, R. D., Kubicka, S. & Arnold, D. Treatment decisions in metastatic colorectal cancer \u2013 Beyond first and second line combination therapies. Cancer Treat. Rev. 59, 54\u201360 (2017).","journal-title":"Cancer Treat. Rev."},{"key":"52006_CR4","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/annonc\/mdx738","volume":"29","author":"T Yoshino","year":"2018","unstructured":"Yoshino, T. et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO\u2013ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann. Oncol. 29, 44\u201370 (2018).","journal-title":"Ann. Oncol."},{"key":"52006_CR5","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","volume":"372","author":"RJ Mayer","year":"2015","unstructured":"Mayer, R. J. et al. Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer. N Engl. J. Med. 372, 1909\u20131919 (2015).","journal-title":"N Engl. J. Med."},{"key":"52006_CR6","unstructured":"Kanoko, M. Drug to replace chemotherapy may reshape cancer care. Bloomberg News (2019). https:\/\/www.bloomberg.com\/news\/articles\/2019-06-11\/drug-to-replace-chemotherapy-may-reshape-cancer-care"},{"key":"52006_CR7","unstructured":"U.S. Food and Drug Administration. FDA approves gemtuzumab ozogamicin for CD33-positive AML. U.S. Food and Drug Administration (FDA) (2017). https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-gemtuzumab-ozogamicin-cd33-positive-aml"},{"key":"52006_CR8","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu, Z., Li, S., Han, S., Shi, C. & Zhang, Y. Antibody\u2013drug conjugate: the biological missile for targeted cancer therapy. Signal. Transduct. Target. Ther. 7, 93 (2022).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"52006_CR9","doi-asserted-by":"publisher","first-page":"3886","DOI":"10.3390\/cancers15153886","volume":"15","author":"P Gogia","year":"2023","unstructured":"Gogia, P., Ashraf, H., Bhasin, S. & Xu, Y. Antibody\u2013Drug Conjugates: A Review of Approved Drugs and Their Clinical Level of Evidence. Cancers 15, 3886 (2023).","journal-title":"Cancers"},{"key":"52006_CR10","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13058-021-01459-y","volume":"23","author":"E Ferraro","year":"2021","unstructured":"Ferraro, E., Drago, J. Z. & Modi, S. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions. Breast Cancer Res. 23, 84 (2021).","journal-title":"Breast Cancer Res."},{"key":"52006_CR11","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3390\/cancers14010154","volume":"14","author":"E D\u00edaz-Rodr\u00edguez","year":"2021","unstructured":"D\u00edaz-Rodr\u00edguez, E., Gandullo-S\u00e1nchez, L., Oca\u00f1a, A. & Pandiella, A. Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs. Cancers 14, 154 (2021).","journal-title":"Cancers"},{"key":"52006_CR12","doi-asserted-by":"publisher","unstructured":"Zheng-Lin, B. & Bekaii-Saab, T. S. Treatment options for HER2-expressing colorectal cancer: Updates and recent approvals. Ther. Adv. Med. Oncol. 16, 17588359231225037. https:\/\/doi.org\/10.1177\/17588359231225037 (2024).","DOI":"10.1177\/17588359231225037"},{"key":"52006_CR13","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher, D., Liberati, A., Tetzlaff, J. & Altman, D. G. The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 6, e1000097 (2009).","journal-title":"PLoS Med."},{"key":"52006_CR14","doi-asserted-by":"publisher","unstructured":"Sterne, J. A. et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ i4919 https:\/\/doi.org\/10.1136\/bmj.i4919 (2016).","DOI":"10.1136\/bmj.i4919"},{"key":"52006_CR15","unstructured":"Li, B. T. et al. Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study. Lancet Oncol. 25, 707 EP \u2013 719 (2024)."},{"key":"52006_CR16","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41698-024-00698-4","volume":"8","author":"S Thavaneswaran","year":"2024","unstructured":"Thavaneswaran, S. et al. A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation. npj Precis Onc. 8, 195 (2024).","journal-title":"npj Precis Onc"},{"key":"52006_CR17","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1158\/2159-8290.CD-19-1014","volume":"10","author":"J Tsurutani","year":"2020","unstructured":"Tsurutani, J. et al. Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors. Cancer Discov. 10, 688\u2013701 (2020).","journal-title":"Cancer Discov."},{"key":"52006_CR18","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.1200\/JCO.23.02626","volume":"42","author":"M Yagisawa","year":"2024","unstructured":"Yagisawa, M. et al. Trastuzumab Deruxtecan in Advanced Solid Tumors With Human Epidermal Growth Factor Receptor 2 Amplification Identified by Plasma Cell-Free DNA Testing: A Multicenter, Single-Arm, Phase II Basket Trial. JCO 42, 3817\u20133825 (2024).","journal-title":"JCO"},{"key":"52006_CR19","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41698-024-00687-7","volume":"8","author":"J Zhang","year":"2024","unstructured":"Zhang, J. et al. First-in-human study of DP303c, a HER2-targeted antibody-drug conjugate in patients with HER2 positive solid tumors. npj Precis Onc. 8, 200 (2024).","journal-title":"npj Precis Onc"},{"key":"52006_CR20","first-page":"18","volume":"5","author":"X Zhang","year":"2022","unstructured":"Zhang, X. et al. Novel development strategies and challenges for anti-Her2 antibody-drug conjugates. Antib. Ther. 5, 18\u201329 (2022).","journal-title":"Antib. Ther."},{"key":"52006_CR21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi, S. et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl. J. Med. 387, 9\u201320 (2022).","journal-title":"N Engl. J. Med."},{"key":"52006_CR22","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1186\/s12935-025-04039-8","volume":"25","author":"G Noorkhajavi","year":"2025","unstructured":"Noorkhajavi, G. et al. Recent clinical advances in nonconjugated antibodies and antibody-drug conjugates for colorectal cancer treatment. Cancer Cell. Int. 25, 395 (2025).","journal-title":"Cancer Cell. Int."},{"key":"52006_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1080\/13543784.2019.1555583","volume":"28","author":"A La Salvia","year":"2019","unstructured":"La Salvia, A., Lopez-Gomez, V. & Garcia-Carbonero, R. HER2-targeted therapy: an emerging strategy in advanced colorectal cancer. Expert Opin. Investig. Drugs. 28, 29\u201338 (2019).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"52006_CR24","doi-asserted-by":"publisher","first-page":"7285","DOI":"10.3390\/ijms26157285","volume":"26","author":"M Ratti","year":"2025","unstructured":"Ratti, M. et al. Fighting HER2 in Gastric Cancer: Current Approaches and Future Landscapes. IJMS 26, 7285 (2025).","journal-title":"IJMS"},{"key":"52006_CR25","doi-asserted-by":"publisher","first-page":"872","DOI":"10.3390\/biomedicines9080872","volume":"9","author":"C Mckertish","year":"2021","unstructured":"Mckertish, C. & Kayser, V. Advances and Limitations of Antibody Drug Conjugates for Cancer. Biomedicines 9, 872 (2021).","journal-title":"Biomedicines"},{"key":"52006_CR26","doi-asserted-by":"publisher","first-page":"100118","DOI":"10.1016\/j.esmogo.2024.100118","volume":"7","author":"BC K\u00f6hler","year":"2025","unstructured":"K\u00f6hler, B. C. et al. TROPHIT1\u2014a randomized, open-label, multicenter, phase II\/III trial of sacituzumab govitecan compared to standard of care in metastatic colorectal cancer patients. ESMO Gastrointest. Oncol. 7, 100118 (2025).","journal-title":"ESMO Gastrointest. Oncol."},{"issue":"2","key":"52006_CR27","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s40268-024-00478-2","volume":"24","author":"S Bellino","year":"2024","unstructured":"Bellino, S. & La Salvia, A. The Importance of Patient Reported Outcomes in Oncology Clinical Trials and Clinical Practice to Inform Regulatory and Healthcare Decision-Making. Drugs R D. 24 (2), 123\u2013127. https:\/\/doi.org\/10.1007\/s40268-024-00478-2 (2024).","journal-title":"Drugs R D"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52006-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52006-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52006-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T22:53:11Z","timestamp":1784674391000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52006-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["52006"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-52006-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"10 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The requirement for informed consent was waived due to the design of the study.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"22863"}}